Glucuronic acid

Other Names

(2S,3S,4S,5R)-2,3,4,5-Tetrahydroxy-6-oxohexanoic acid(2S,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid(2S,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acidAcide D-glucuroniquealdehydo-D-Glucuronatealdehydo-D-Glucuronic acidalpha-D-Glucuronic acidD-GLCAD-gluco-Hexulonic acidD-GlucopyranuronateD-Glucopyranuronic acidD-GlucuronateD-Glucuronic acidD-Glucuronic acid, free acidD-Glucurono acidD-Glucuronsäuredextro-Glucuronic acidGCAGlucopyranuronateGlucosiduronic acidGlucuronateGlycuronic acid

Synopsis

Glucuronic Acid

1. Identity: Chemical Names, Structure, and Natural Sources

Chemical Identity

Glucuronic acid (abbreviated GCA, from the Ancient Greek γλεῦκος + οὖρον, meaning "sweet wine/must + urine") is a uronic acid that was first isolated from urine, hence the family name "uronic acid." It is a uronic acid derived from glucose, where the sixth carbon atom of glucose has been oxidized to a carboxyl group. This makes it a sugar acid rather than a simple sugar.

Glucuronic acid carries the IUPAC name 3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid and bears the CAS number 6556-12-3. Its molecular formula is C₆H₁₀O₇. Glucuronic acid can combine with hydroxyl (–OH), carboxyl (–COOH), or amino (–NH₂) groups to form a glucuronide. The biologically active form predominant in mammals is D-glucuronic acid, which participates in the vast majority of known biochemical functions.

Glucuronic acid is synthesized from glucose in the uronic pathway, an alternative oxidative pathway for glucose that does not result in the production of adenosine triphosphate (ATP). In this pathway, glucose-6-phosphate is converted to glucose-1-phosphate, which subsequently reacts with uridine triphosphate to form uridine diphosphate glucose (UDP-glucose). This compound is then oxidized at the six-carbon position in a two-step process by the NAD-dependent enzyme UDP-glucose dehydrogenase to form UDP-glucuronate.

Natural Sources

Glucuronic acid is found in many gums such as gum arabic (approximately 18%), xanthan, and kombucha tea, and is important for the metabolism of microorganisms, plants, and animals. Glucuronic acid (GlcA) is a component of proteoglycans, glycosaminoglycans, xylans, and numerous endogenous and xenobiotic glycosides.

Glucuronic acid and gluconic acid are fermentation products found in kombucha tea. The human body is also capable of synthesizing glucuronic acid endogenously from glucose through the uronic acid pathway.

Calcium D-glucarate, a related compound, is found naturally in small amounts in mammals including humans. Glucaric acid is also found in many fruits and vegetables, with the highest concentrations found in oranges, apples, grapefruit, and cruciferous vegetables.

Common Forms and Preparations

As a dietary supplement or pharmacological ingredient, glucuronic acid appears in several forms:

Free glucuronic acid: Dr. Ishidate and Dr. Masasi Okada first succeeded in obtaining glucuronic acid lactone in crystal form from glucose using chemical synthesis in 1950. Subsequently, Dr. Yuji Imai and Mr. Masao Ishihara succeeded in producing glucuronic acid using a mass-production method in a laboratory setting in the same year.
Calcium D-glucarate (calcium D-glucarate): The calcium salt of D-glucaric acid, a substance produced naturally in small amounts by mammals including humans.
Kombucha beverages: Kombucha is a beverage made by fermenting sugared tea using a symbiotic culture of bacteria and yeasts, and is one of the most recognized dietary sources of glucuronic acid.
Glucuronide-containing polysaccharides: Hyaluronic acid is a glycosaminoglycan polysaccharide composed of glucuronic acid and N-acetylglucosamine chains and is an essential component of the extracellular matrix. It is available as an oral or injectable supplement in its own right.
Sodium glucuronate: Sodium glucuronate can be produced by the direct oxidation of starch with concentrated nitric acid.

2. Traditional and Historical Use

Early Scientific Recognition

The importance of glucuronic acid was first formally recognized in the early 20th century, when researchers discovered its involvement in the body's mechanism for making substances more water-soluble, thus facilitating their excretion. Glucuronic acid was found to serve as a key component in the formation of glucuronides, which are conjugates essential for the metabolism of various drugs, hormones, and toxins.

Glucuronic acid was known to be a detoxifying agent in humans, excreted in urine in a conjugated form. Dr. Morizo Ishidate of Tokyo University sought to isolate the compound and determine its metabolic system and role in living organisms. Dr. Tsuyoshi Shimozawa studied the metabolic course of glucuronic acid in rats during the period 1943–1944 under the leadership of Dr. Ishidate. Japan's Ministry of Health and Welfare approved glucuronic acid as a medicine in 1951, marking one of the first institutional recognitions of the compound as a pharmacologically relevant substance.

Ethnobotanical Context

Plants rich in glucuronides, such as dandelion and burdock root, have been traditionally used in Europe and Asia to aid in the cleansing of the blood and to promote organ function. These uses predate the isolation of glucuronic acid itself; the traditional value attributed to these plants was understood retrospectively as related, in part, to their glucuronide content.

Glucuronic acid and its derivatives have been recognized in traditional medicine for their contribution to health and wellness. Early 20th century research highlighted the crucial function of glucuronides in facilitating the elimination of toxins, drugs, and metabolic waste products from the body by making them water-soluble for excretion via urine.

Kombucha, one of the richest dietary sources of glucuronic acid, has its own centuries-long history of use. Kombucha consumption has been associated with various health effects, including reduction of cholesterol levels and blood pressure, reduction of cancer propagation, and improvement of liver, immune system, and gastrointestinal functions. However, many of these claims originate from traditional or anecdotal sources, with rigorous clinical evidence remaining sparse (see Section 5 below).

3. Key Constituents, Active Forms, and Mechanisms of Action

UDP-Glucuronic Acid: The Active Intermediate

UDP-glucuronate is the form of glucuronic acid that can be incorporated into proteoglycans or conjugated with steroid hormones, certain drugs, or bilirubin. The first steps toward its synthesis are identical to those of glycogen synthesis: formation of glucose-6-phosphate, its isomerization to glucose-1-phosphate, and activation of glucose-1-phosphate to form UDP-glucose. UDP-glucose is then oxidized to UDP-glucuronic acid by NAD⁺ and UDP-glucose dehydrogenase.

UDP-glucuronic acid is utilized in biosynthetic reactions that involve condensation of glucuronic acid with a variety of molecules to form an ether (glycoside), an ester, or an amide, depending on the nature of the acceptor molecule.

Glucuronidation: Phase II Detoxification

The conjugation of xenobiotic molecules with hydrophilic molecular species such as glucuronic acid is known as phase II metabolism. Glucuronidation occurs mainly in the liver, although the enzyme responsible for its catalysis, UDP-glucuronosyltransferase, has been found in all major body organs. Glucuronidation is often involved in the drug metabolism of substances such as drugs, pollutants, bilirubin, androgens, estrogens, mineralocorticoids, glucocorticoids, fatty acid derivatives, retinoids, and bile acids.

Glucuronidation consists of the transfer of the glucuronic acid component of uridine diphosphate glucuronic acid to a substrate by any of several types of UDP-glucuronosyltransferase. UDP-glucuronic acid (glucuronic acid linked via a glycosidic bond to uridine diphosphate) is an intermediate in the process and is formed in the liver.

The substances resulting from glucuronidation are known as glucuronides (or glucuronosides) and are typically much more water-soluble than the non-glucuronic acid-containing substances from which they were originally synthesised.

Phase II glucuronidation is catalyzed by the superfamily of enzymes, UDP-glucuronosyltransferases (UGTs), which catalyze the covalent addition of glucuronic acid to a wide range of lipophilic chemicals, converting them to more polar, less reactive compounds. Research suggests that 40% to 70% of all medications are subject to glucuronidation reactions in humans, highlighting the significance of this conjugation enzyme family.

UGT Enzyme Families

The UGT family has been classified into two subfamilies, UGT1 and UGT2, on the basis of evolutionary divergence. The UGT1 locus is located on chromosome 2q37 and encodes multiple unique exons producing nine functional UGT1A isoforms: UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10. In the liver — the most important tissue for detoxification — UGT1A1, UGT1A3, UGT1A4, UGT1A6, and UGT1A9 are expressed.

UGT1A6, for example, helps with transforming bilirubin, hormones, and certain drugs (such as aspirin and acetaminophen) into water-soluble metabolites for excretion. UGT2B7 is involved in the glucuronidation of various drugs, including morphine, codeine, and zidovudine. UGT2B15 is responsible for the glucuronidation of testosterone and other androgens.

Structural Role in Glycosaminoglycans

Glycosaminoglycans are linear polysaccharide chains of repeating disaccharide units, with each disaccharide unit consisting of hexosamine and uronic acid. Heparan sulfate (HS) is a polymer of disaccharide units composed of N-acetylglucosamine and glucuronic acid, whereas chondroitin sulfate (CS) is composed of N-acetylgalactosamine and glucuronic acid. Hyaluronic acid (HA) is a longer, non-sulfated disaccharide polymer of N-acetylglucosamine and glucuronic acid, with molecular masses ranging up to millions of Daltons.

Glycosaminoglycans (GAGs) are long, linear polysaccharides comprised of repeating disaccharide units with pleiotropic biological functions; non-sulfated HA and sulfated GAGs including dermatan sulfate, chondroitin sulfate, heparan sulfate, and keratan sulfate are all expressed in skin. Their ability to regulate keratinocyte proliferation and differentiation, inflammatory processes, and extracellular matrix composition demonstrates their critical role in regulating skin physiology. The water-binding properties of GAGs and structural qualities, particularly for HA, are crucial for maintaining proper skin form and hydration.

The Uronic Acid Pathway and Its Branches

The glucuronic acid pathway is most active in the liver, kidneys, and intestines. A second product of the uronic pathway is L-ascorbic acid, which is produced in mammals with the exception of humans, primates, and the guinea pig. In a series of reactions, glucuronate is reduced to L-gulonate, which is subsequently converted to L-ascorbic acid. Humans lack the final enzyme (L-gulonolactone oxidase) required for ascorbic acid synthesis from this pathway, making vitamin C dietary-essential in humans.

Glucuronic acid synthesis may be stimulated when the consumption of substances that are excreted as glucuronides is increased, or when steroids and barbiturates — which induce the microsomal P-450 system — are consumed.

Antioxidant and Anti-Inflammatory Properties

Glucuronic acid is recognized for its various physiological benefits, including detoxification, antioxidation, and anti-inflammation. The ability of glucuronides to influence the biological activity of endogenous estrogens after their deconjugation at the cellular level has been observed. In addition, glucuronides have a protective function in relation to polyunsaturated fatty acids (PUFA) by preventing lipid peroxidation, contributing to preservation of PUFA health properties.

4. Scientific Evidence by Area of Use

4.1 Liver Detoxification and Hepatoprotection

Glucuronidation is an important phase II reaction catalyzed by UGTs, which are enzymes involved in phase II drug metabolism; approximately 35% of therapeutic drugs undergo conjugation with glucuronic acid prior to elimination. The process of glucuronidation plays a vital role in the body's detoxification mechanisms by facilitating the conversion of lipophilic compounds into more water-soluble forms, thereby enhancing the excretion of potentially harmful substances.

Although previous research supports beneficial hepatoprotective effects of glucuronic acid consumption from kombucha, these effects are mainly attributed to the tea phytochemicals. Glucuronic acid is contained naturally in kombucha beverages due to the associations between bacteria and yeasts during fermentation. The mechanistic evidence for hepatoprotection is principally biochemical and animal-based, with very limited human-specific data for glucuronic acid supplementation in isolation.

While there is robust biochemical evidence for its physiological role, clinical studies specifically evaluating the effects of supplemental glucuronic acid in humans are limited.

4.2 Bilirubin Metabolism and Jaundice Disorders

Glucuronic acid's role in bilirubin conjugation is one of the most rigorously characterized aspects of its biochemistry and is directly implicated in recognized clinical disorders.

The bilirubin-UGT enzyme performs a chemical reaction called glucuronidation. During this reaction, the enzyme transfers glucuronic acid to unconjugated bilirubin, converting it to conjugated bilirubin. Glucuronidation makes bilirubin dissolvable in water so that it can be removed from the body.

Gilbert's Syndrome: The molecular basis of Gilbert's syndrome lies in the impairment of the conjugation of bilirubin with glucuronic acid in the liver. This is because the rate-limiting metabolic step in the transfer of unconjugated bilirubin from the systemic circulation into bile is bilirubin glucuronosylation. It is primarily due to reduced activity of the conjugating enzyme bilirubin UDP glucuronosyl transferase (UGT1A1), in Caucasians commonly related to a UGT1A1*28 polymorphism. The prevalence of Gilbert syndrome ranges from 2% to 20%, depending on an individual's ethnicity. Reduced glucuronidation of bilirubin leads to unconjugated hyperbilirubinemia and recurrent episodes of jaundice.

Crigler-Najjar Syndrome: Crigler-Najjar syndrome is characterized by the absence or decreased activity of UDP-glucuronosyltransferase (UGT), an enzyme required for glucuronidation of unconjugated bilirubin in the liver. This deficiency is a significant cause of congenital nonhemolytic jaundice.

Evidence strength: The biochemical and genetic evidence linking glucuronic acid conjugation to bilirubin metabolism is very strong and established. However, this evidence pertains to the endogenous system; there is no clinical evidence supporting exogenous glucuronic acid supplementation as a treatment for these disorders.

4.3 Cancer Chemoprevention (via Calcium D-Glucarate)

Much of the research examining glucuronic acid in a cancer-related context has focused on calcium D-glucarate, a metabolic precursor/related compound that inhibits the enzyme beta-glucuronidase.

Oral supplementation of calcium D-glucarate has been shown to inhibit beta-glucuronidase, an enzyme produced by colonic microflora and involved in Phase II liver detoxification. Elevated beta-glucuronidase activity is associated with an increased risk for various cancers, particularly hormone-dependent cancers such as breast, prostate, and colon cancers.

D-glucaro-1,4-lactone (1,4-GL), a derivative of D-glucaric acid, increases detoxification of carcinogens and tumor promoters/progressors by inhibiting beta-glucuronidase and preventing hydrolysis of their glucuronides. D-glucaric acid is a nontoxic, natural compound, and one of its key derivatives is the potent beta-glucuronidase inhibitor 1,4-GL.

Walaszek et al. (1997) demonstrated that D-glucarate supplementation inhibited beta-glucuronidase activity and reduced tumor incidence in animal models of breast, colon, and liver cancer. Although lab studies suggest anticancer effects, calcium glucarate has not been shown to treat or prevent cancer in humans.

Rigorous human clinical trials specifically for calcium D-glucarate in estrogen metabolism or cancer prevention are lacking. The supplement's popularity is largely based on the well-characterized biochemistry, animal data, and logical extrapolation to human estrogen metabolism rather than direct human RCT evidence.

Evidence strength: Preclinical (animal and in vitro) evidence for anticancer activity via beta-glucuronidase inhibition is consistent; human clinical trial evidence is currently absent. Classification is: mechanistically plausible, preclinically supported, human evidence lacking.

4.4 Hormone Metabolism and Estrogen Clearance

Gut bacteria produce beta-glucuronidase, which can remove the glucuronic acid tag from conjugated estrogens and allow estrogen to be reabsorbed back into circulation. Calcium D-glucarate's metabolite (D-glucaro-1,4-lactone) inhibits this bacterial enzyme, helping conjugated estrogen remain conjugated and be eliminated as intended.

Other potential clinical applications of oral calcium D-glucarate include regulation of estrogen metabolism and use as a lipid-lowering agent.

Evidence strength: The mechanism of glucuronic acid conjugation of estrogens and the reversal of that conjugation by bacterial beta-glucuronidase is well-established biochemically. Whether supplemental calcium D-glucarate substantially modifies circulating estrogen levels in humans has not been demonstrated in well-powered randomized controlled trials.

4.5 Kombucha, Glucuronic Acid, and Cardiometabolic Health

A systematic review that searched the Cochrane CENTRAL, MEDLINE/PubMed, and Embase databases (following PRISMA guidelines and registered on PROSPERO) identified eight clinical trials — two pre- and post-interventions and six randomized controlled trials — with durations ranging from 10 days to 10 weeks, examining the health effects of kombucha consumption in humans.

In one of those studies, consumption of kombucha for four weeks in adults with type 2 diabetes mellitus led to a significant fasting blood glucose reduction in comparison with baseline, a finding not observed in the placebo-treated group.

Although kombucha has been associated with antioxidant, antimicrobial, probiotic, antidiabetic, and anticancer activities, strong scientific evidence in humans remains limited. Further clinical studies are needed to substantiate kombucha's health benefits in humans.

Importantly, as of the most recent reviews, there is no report of empirical evidence of the health benefits of kombucha specifically in human subjects, and clinical trials examining kombucha's potential human health benefits need to be further addressed.

Evidence strength: Kombucha contains glucuronic acid alongside many other bioactive compounds. The few existing human trials are short-duration and have small sample sizes. It is not possible, based on current evidence, to isolate the contribution of glucuronic acid specifically to any health outcomes observed in kombucha studies.

4.6 Connective Tissue and Joint Health

Glucuronic acid is a building block for critical components of cartilage and connective tissues, such as hyaluronic acid. Chondroitin sulfate is located in cartilages and the epithelia. Hyaluronic acid naturally occurs as a regular non-sulfated macromolecule formed by a linear disaccharide sequence of glucuronic acid linked to N-acetylglucosamine.

The evidence base for glucuronic acid's structural contributions to joint and connective tissue health is understood primarily through the clinical literature on hyaluronic acid and chondroitin sulfate supplementation, both of which are composed of glucuronic acid-containing disaccharide repeats. Hyaluronic acid has been approved by a number of countries as a novel food ingredient, additive, healthy food, or dietary supplement.

Evidence strength: Strong mechanistic/structural evidence. Clinical evidence for joint benefit exists for hyaluronic acid and chondroitin sulfate as such; however, isolated glucuronic acid supplementation for joint health has not been studied in human clinical trials.

4.7 Drug Metabolism and the Enterohepatic Cycle

Some anti-cancer drugs are converted by liver UDP-glucuronosyltransferases to form drug-glucuronide conjugates. These sugar-conjugated metabolites are generally inactive and can be safely excreted via the biliary system into the gastrointestinal tract. However, beta-glucuronidase (βGUS) enzymes expressed by commensal gut bacteria can remove the glucuronic acid moiety, producing the reactivated drug and triggering dose-limiting side effects.

Over 20 of 100 commonly surveyed medications are metabolized through glucuronidation and then reactivated by beta-glucuronidases. A concrete case is the chemotherapeutic agent irinotecan. Additional strong evidence was presented for certain NSAIDs (e.g., diclofenac, ketoprofen, and indomethacin), in which their metabolites were found to be reactivated by gut microbial beta-glucuronidases, causing intestinal toxicity.

Evidence strength: Mechanistically well-characterized. Clinically relevant for understanding drug side effects. The research describes the endogenous role of glucuronic acid in drug metabolism, not supplementation outcomes.

5. Body Systems Associated with Glucuronic Acid

Hepatic (Liver): The process of glucuronidation occurs primarily in the liver, where UDP-glucuronic acid is formed as an intermediary product. All major Phase II conjugation of drugs, hormones, and toxins dependent on glucuronic acid centers in hepatocytes.
Musculoskeletal/Connective Tissue: Glucuronic acid is a structural monomer of hyaluronic acid and chondroitin sulfate — major constituents of cartilage, synovial fluid, tendons, and skin extracellular matrix.
Gastrointestinal: Glucuronidation occurs primarily in the liver, but UGTs are present in other organs including the kidney, pancreas, gut, and brain. Gut microbial beta-glucuronidases play a significant role in the enterohepatic recycling of conjugated compounds.
Endocrine (Hormonal): Many substances, including hormones and potentially toxic ingested substances, are excreted as conjugates with glucuronic acid, known as glucuronides.
Neurological: UGTs present in the brain protect local tissues from harmful and toxic chemicals, indicating a glucuronic acid-dependent protective mechanism in the central nervous system.
Renal: The glucuronic acid pathway is most active in the liver, kidneys, and intestines, and the kidneys play a key role in excreting glucuronide conjugates via urine.

6. Dosage Forms and Dosages Reported in Studies

Glucuronic acid itself does not have a standardized or well-established supplemental dosage recognized by major regulatory bodies (NIH ODS, EFSA, or EMA). Most relevant human dosage data come from studies on:

Calcium D-glucarate: Oral supplementation of calcium D-glucarate has been shown to inhibit beta-glucuronidase. The Alternative Medicine Review monograph on calcium D-glucarate (published in Alt Med Rev, 2002) reported animal-based dosing protocols, but human clinical trials establishing effective doses are lacking in peer-reviewed literature.
Kombucha (as a glucuronic acid-containing beverage): Clinical trials examining kombucha had durations ranging from 10 days to 10 weeks, with varying daily volumes used. The glucuronic acid concentration in kombucha varies significantly depending on fermentation conditions, substrate, and microbial strains. The content of the beneficial or toxic components is very variable because it depends on its manufacturing process.
Hyaluronic acid (as a glucuronic acid-containing polymer): Hyaluronic acid has been approved by a number of countries as a novel food ingredient, additive, healthy food, or dietary supplement, and is typically available in oral and injectable dosage forms at doses studied in the range of 80 mg to 200 mg/day orally in clinical trials, though this pertains to hyaluronic acid as a whole polymer, not free glucuronic acid.

No authoritative source identified in this review specifies a validated oral dose of free glucuronic acid for supplemental use in humans.

7. Safety Considerations and Notable Interactions

General Endogenous Availability

Glucuronic acid deficiency is uncommon because the body can produce it on its own. However, insufficient glucuronic acid production may occur in cases of poor nutrient intake or metabolic disorders.

Exhaustion of Glucuronic Acid by Polypharmacy

It is possible to exhaust the body's supply of glucuronic acid by combining multiple drugs or substances whose metabolism and excretion are dependent on glucuronidation. This is a pharmacokinetically established concern in patients taking multiple medications that are all conjugated via glucuronidation.

Glucuronic Acid, Inflammation, and Pain

Glucuronic acid, as well as the glucuronidated metabolite of ethanol, ethyl glucuronide (ETG), acts on toll-like receptor 4 to aggravate both acute and chronic inflammatory conditions and increases the perceived severity of pain in patients with chronic pain conditions, via up-regulation of the production and release of endogenous inflammatory signaling molecules within the body. This represents a notable and source-backed safety consideration that runs counter to simplistic "detoxification" narratives about glucuronic acid.

Drug–Drug Interactions via UGT Inhibition and Induction

Drug–drug interactions (DDIs) involving glucuronidated drugs have historically attracted little attention, with a perception that interactions are of minor clinical relevance. However, a detailed review critically examines the scope of DDIs that result in altered exposure of glucuronidated drugs, including inhibition and induction of UDP-glucuronosyltransferase (UGT) enzymes and the potential interplay with drug transporters.

Glucuronidation can modulate the potency of some drugs: the 6-glucuronide of morphine is a more potent analgesic than the parent compound, whereas the 3-glucuronide is a morphine antagonist. Additionally, steroid glucuronidation can produce more active or toxic metabolites under pathophysiological conditions or during steroid therapies.

Gilbert's Syndrome and Drug Sensitivity

Gilbert syndrome is a benign, inherited disorder of bilirubin metabolism without the risk of progressive liver disease, hepatic decompensation, or increased mortality. However, these patients are at increased risk from drug toxicity when exposed to medications that suppress or affect UGT1A1 activity. A thorough history should be taken to ascertain whether the patient is taking drugs that are metabolized through glucuronidation, such as tolbutamide, rifamycin, human immunodeficiency virus protease inhibitors, gemfibrozil, and statins, which could contribute to altered bilirubin metabolism.

Gut Microbial Beta-Glucuronidase and Drug Reactivation

Microbial beta-glucuronidases (GUSs) cause severe gut toxicities that limit the efficacy of cancer drugs and other therapeutics. Selective inhibitors of bacterial GUS have been shown to alleviate these side effects. In the case of irinotecan and NSAIDs, the effect of beta-glucuronidase on drug metabolism can be severe. Other drug interactions may be less severe and thus undocumented.

Safety of Kombucha as a Glucuronic Acid Source

There is no sufficient evidence to generalize the adverse effects of kombucha consumption. Consumption of kombucha could be considered a safe practice in healthy populations due to its hepatoprotective effects. However, in persons with underlying illness, other conditions such as pregnancy, and hypersensitivity to some kombucha components, a restriction in its consumption must be considered.

8. Summary of Evidence Strength

Endogenous biochemical roles (Phase II metabolism, bilirubin conjugation, GAG synthesis): Extensively characterized; biochemical and genetic evidence is robust and clinically established.
Glucuronic acid in detoxification/liver health as a supplement: Mechanistically well-grounded; direct human clinical trial evidence for supplemental glucuronic acid specifically is currently lacking.
Calcium D-glucarate for cancer chemoprevention and estrogen metabolism: Animal and in vitro evidence is consistent; human RCT evidence is absent.
Kombucha for human health endpoints: A small number of human RCTs exist; results are preliminary and the contribution of glucuronic acid specifically cannot be isolated from other kombucha constituents.
Connective tissue and joint support via GAG-containing supplements: Clinical evidence exists for hyaluronic acid and chondroitin sulfate as whole compounds; not for free glucuronic acid supplementation.

References

Health Conditions

Health conditions that Glucuronic acid may help support.

No conditions available.

Body Systems

Body systems that Glucuronic acid may help support.

No body systems available.